AVTX

AVTX

USD

Avalo Therapeutics Inc. Common Stock

$4.760-0.015 (-0.314%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$4.775

الأعلى

$4.950

الأدنى

$4.653

الحجم

0.04M

أساسيات الشركة

القيمة السوقية

51.5M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.07M

البورصة

NCM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $3.39الحالي $4.760الأعلى $16

تقرير تحليل الذكاء الاصطناعي

آخر تحديث: ١٠ يونيو ٢٠٢٥
تم إنشاؤه بواسطة الذكاء الاصطناعيمصدر البيانات: Yahoo Finance, Bloomberg, SEC

AVTX: Avalo Therapeutics Inc. Common Stock – What's Happening and What's Next?

Stock Symbol: AVTX Generate Date: 2025-06-10 02:00:19

Let's break down what's been going on with Avalo Therapeutics and what the data might suggest for its path forward.

The Latest Buzz: Investor Conferences on the Horizon

Avalo Therapeutics recently announced they'll be participating in upcoming investor conferences. This kind of news, published on May 27, 2025, usually carries a positive undertone. Why? Because it means the company is actively engaging with the investment community. They're putting themselves out there, aiming to attract new investors or reassure existing ones. For a clinical-stage biotech company like Avalo, which focuses on immune dysregulation treatments, getting their story out to potential funders is pretty important. It's a sign they're looking to build interest and potentially secure future capital, which is generally a good thing for growth.

Price Check: A Rollercoaster Ride, Then a Dip

Looking at the last few months, AVTX has seen some significant swings. Back in March, it was trading around the $7-$8 range, even hitting a high of $9.70 on March 25. But since then, it's been a steady slide downwards. By early May, the price had dropped into the $4-$5 range, and it continued to drift lower, touching lows around $3.60 in late May.

More recently, though, we've seen a bit of a bounce. From a low of $3.58 on May 27 (the same day the news about investor conferences came out), the stock has climbed back up, closing at $4.56 on June 9. That's a decent jump from its recent bottom.

Now, what about the immediate future? Our AI model from AIPredictStock.com suggests a pretty flat day today (0.00% change), followed by a slight dip tomorrow (-0.28%), and then a small rebound the day after (+0.37%). These are very minor predicted movements, hinting at a period of consolidation or sideways trading right after this recent uptick.

Putting It All Together: What Does This Mean for AVTX?

The recent news about investor conferences is a positive signal, suggesting the company is proactive. This aligns with the stock's recent bounce from its lows. However, the longer-term trend has been clearly downward.

Given the positive news sentiment and the stock's recent recovery from its bottom, there's a sense that the immediate pressure might be easing. The AI's predictions for very small, mixed movements over the next couple of days suggest things might stabilize around current levels after the recent climb.

Potential Strategy Ideas (Just Food for Thought):

  • For those considering getting in: The current price, around $4.56, is above the AI's suggested entry points of $4.17 to $4.30. If the stock were to pull back slightly towards that $4.30 area, it might be a spot to watch, especially if the positive news continues to build. This range aligns with recent support levels before the latest upward move.
  • Managing Risk: A potential stop-loss level to consider, based on the data, could be around $3.65. This is below recent lows and would help limit potential losses if the stock were to reverse its recent upward trend and fall back significantly.
  • Taking Profits: The AI suggests a potential target price of $1.00, which seems quite low compared to current prices and historical data. However, another suggested take-profit level is $4.33. This seems more aligned with the recent price action. If the stock continues its upward momentum, watching for resistance around the $4.33 mark or slightly higher could be a strategy for short-term gains.

It's worth noting that Avalo Therapeutics is a clinical-stage biotech company. These types of companies can be quite volatile, with their stock prices often reacting strongly to news about clinical trials or regulatory approvals. Their P/E ratio is currently 0.0x, which is significantly below the industry average, suggesting it could be undervalued from a fundamental perspective. Also, the company boasts a very high Return on Equity at 678.2%, which is quite impressive. However, it's a smaller company with lower trading volume, which can sometimes lead to bigger price swings.

Important Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks carries inherent risks, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial professional before making any investment decisions.

أخبار ذات صلة

GlobeNewswire

Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that

عرض المزيد
Avalo Therapeutics to Participate in Upcoming Investor Conferences

تنبؤ الذكاء الاصطناعيBeta

توصية الذكاء الاصطناعي

صعودي

تم التحديث في: ١٢ يونيو ٢٠٢٥، ٠٤:١٩ م

هبوطيمحايدصعودي

57.8% الثقة

المخاطر والتداول

مستوى المخاطرة3/5
مخاطرة متوسطة
مناسب لـ
قيمة
دليل التداول

نقطة الدخول

$4.72

جني الأرباح

$5.64

وقف الخسارة

$4.32

العوامل الرئيسية

مؤشر PDI 36.3 فوق مؤشر MDI 32.5 مع مؤشر ADX 11.0، مما يشير إلى اتجاه صعودي
السعر الحالي قريب جدًا من مستوى الدعم (4.70 دولار)، مما يشير إلى فرصة شراء قوية
مؤشر MACD -0.0061 فوق خط الإشارة -0.0242، مما يشير إلى تقاطع صعودي

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.